Skip to main content

Market Overview

Recap: Haemonetics Q4 Earnings



Shares of Haemonetics (NYSE:HAE) rose 2.1% in pre-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share were down 33.33% over the past year to $0.46, which missed the estimate of $0.67.

Revenue of $225,029,000 declined by 5.65% from the same period last year, which beat the estimate of $222,980,000.


The upcoming fiscal year's EPS expected to be between $2.60 and $3.00.

The upcoming fiscal year's revenue expected to be between $983,623,000 and $1,027,000,000.

How To Listen To The Conference Call

Date: May 13, 2021

Time: 08:00 AM

ET Webcast URL:

Recent Stock Performance

Company's 52-week high was at $142.11

Company's 52-week low was at $58.16

Price action over last quarter: down 52.92%

Company Description

Haemonetics Corp sells products used to process, handle, and analyze blood. The firm sells products in four categories: Plasma, Hemostasis Management, Blood Center and Cell Processing. The Plasma business includes plasma collection devices and disposables. Hemostasis Management includes devices and methodologies for measuring coagulation characteristics of blood, Blood Center includes blood collection and processing devices and disposables for red cells and Cell Processing include surgical blood salvage systems, specialized blood cell processing systems, disposables and blood transfusion management software.


Related Articles (HAE)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at